Septerna Raises $150M in Series B Financing to Advance Novel GPCR Medicines

South San Francisco, CA, July 11, 2023 (Business Wire) -- Biotech firm Septerna secures $150 million in a Series B funding round to further develop its portfolio of oral small molecule medicines focusing on advancements in hypoparathyroidism treatment. The financing was led by RA Capital Management and includes participation from prestigious investors.

Read full article here.